226256-56-0,Cinacalcet,CaSR modulator, AMG 073, AMG073, AMG-073

Basic Info

Model No.: 226256-56-0

Additional Info

Packaging: AS REQUIRED

Productivity: G,KGS,

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: COMMERCIAL PRODUCTION

Certificate: GMP/ISO

Product Description

Backed by industry experience, we are capable for providing high quality Cinacalcet CAS 226256-56-0. Cinacalcet CAS NO 226256-56-0 is wide used in treatment for secondary hyperparathyroidism in people with chronic kidney disease on dialysis and hypercalcemia in people with parathyroid carcinoma. Cinacalcet can also be used to treat severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy. We can offer Cinacalcet 226256-56-0 range from gram to kilogram grade. Our specification is sterile and micronized. Customers can choose our product at ease..

• Thera. Category: Anti-Hyperparathyroidism
• Cas No.: 226256-56-0
• Synonym: CINACALCET;(aR)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl)propyl]-1-napthalenemethanamine;AMG 073;(aR)-a-Methyl-N-[3-[3-(trifluoromethyl)phenyl)propyl]-1-napthalenemethanamine;N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine;364782-34-3 (Hydrochloride);Cinacalcet [inn];Hsdb 7318
• Molecular Formula: C22H22F3N

• 
  
• Molecular Weight: 357.41
• Specifications: Available on request
• Packing: Export worthy packing
• Material Safety Data Sheet: Available on request

Usage: Cinacalcet(AMG-073) is an orally active, second-generation calcimimetic compound; AMG 073 represents a new class of compounds for the treatment of hyperparathyroidism.Cinacalcet is the only calcimimetic approved for HPT secondary to chronic kidney disease (CDK), parathyroid carcinoma, and, in some countries, primary HPT. Clinical trials showed that cinacalcet reduced PTH and calcemia both in CDK and primary HPT, lowering the risk of bone fractures, surgery, and cardiovascular complications in the former patients. Long-term safety and pharmacoeconomics have to be fully tested yet. Few both in vitro and in vivo studies showed an association between Arg990Gly-CASR polymorphism and cinacalcet sensitivity, though in patients with severe CASR inactivating mutations the drug substantially retained its positive clinical effects.